Published in Hepatitis Weekly, October 27th, 1997
The Consensus Interferon Study Group found a treatment protocol of 9 (mu)g synthetic interferon three times weekly for six months to be safe and effective in reducing serum hepatitis C virus (HCV) RNA concentrations.
Consensus interferon (CIFN) (Amgen Inc., Thousand Oaks, California) is a non-natural, synthetic, recombinant type-1 interferon derived by aligning the sequences of the known interferon alpha (IFN-(alpha)) nonallelic subtypes, and assigning the most commonly observed amino acid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.